2026-06-03 FDA Warning Letter: Hubei Gedian Humanwell Pharmaceutical Co., Ltd. Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
TL;DR
The short version: FDA's Center for Drug Evaluation and Research (CDER) issued a Warning Letter to Hubei Gedian Humanwell Pharmaceutical Co., Ltd. on 2026-06-03 regarding CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. The verbatim letter is published on fda.gov.
Argus analysis
Hubei Gedian Humanwell Pharmaceutical Co., Ltd. received a Warning Letter from FDA's Center for Drug Evaluation and Research (CDER), dated 2026-06-03, regarding CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. The letter follows an FDA inspection and is classified by Argus HQ as high severity, consistent with Current Good Manufacturing Practice violations under 21 CFR Part 211 (drugs) or Part 600 (biologics).
The excerpt below does not contain a machine-extractable 21 CFR section number; FDA classifies this matter as cgmp, which generally concerns Current Good Manufacturing Practice violations under 21 CFR Part 211 (drugs) or Part 600 (biologics), typically covering component testing, cleaning validation, laboratory controls, or investigation of out-of-specification results. See the verbatim letter linked below for FDA's exact citation language.
FDA Warning Letters carry a 15-business-day response window for the recipient to detail corrective actions. Peer compliance teams in the same product category typically use a letter like this one as an external audit trigger, checking whether their own quality system has documented coverage for the cited sections and whether their CAPA log would withstand the same line of inspection questioning.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Hubei Gedian Humanwell Pharmaceutical Co., Ltd. MARCS-CMS 725591 — June 03, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS Reference #: 320-26-93 Product: Drugs Recipient: Recipient Name Dr. Hailin Chen Recipient Title General Manager Hubei Gedian Humanwell Pharmaceutical Co., Ltd. No. 25 Juxian Road Gedian Economic Development District Ezhou Shi Hubei Sheng , 436070 China chenhalin@renfu.com.cn Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-93 June 3, 2026 Dear Dr. Chen: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Hubei Gedian Humanwell Pharmaceutical Co., Ltd., FEI 3004117486, located at No. 25 Juxian Road, Gedian Economic Development District, Ezhou City, Hubei Province, China, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your November 28, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigator observed specific deviations including, but not limited to, the following. 1. Failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specifications. Your firm manufactures (b)(4) for the U.S. market. During the inspection, our investigator observed numerous scratches and (b)(4) stains on the interior API-contact surfaces of your (b)(4) vessels, as well as (b)(4) markings on the lid and rim of the (b)(4) of your (b)(4) vessel. These markings and discolored stains indicate that the integrity of the API-contact surfaces is being compromised which can lead to contamination of your API with particulate matter (e.g., (b)(4) particles) or alter the quality of the API via chemical leachable reactions. In your response, you state that compatibility between the equipment product contact surface material of construction and the chemical process, specifically the (b)(4) and the (b)(4) process, is insufficient. You state that the (b)(4) chemicals used in the process weakens the (b)(4) on the (b)(4) surfaces which leads to (b)(4) manifested as (b)(4) stains/discoloration and scratches. You (b)(4) your (b)(4) and (b)(4) the interior walls and plan to perform preventive (b)(4) maintenance (b)(4) . You (b)(4) the (b)(4) markings on the (b)(4) and lid and replaced the (b)(4) gasket sealing the (b)(4) lid. Your response is inadequate because you do not support the frequency of your preventive…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Hubei Gedian Humanwell Pharmaceutical Co., Ltd. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Hubei Gedian Humanwell Pharmaceutical Co., Ltd. as of 2026-06-09. Argus ingests new FDA enforcement records daily.
- What FDA violations was Hubei Gedian Humanwell Pharmaceutical Co., Ltd. cited for?
- The FDA Warning Letter to Hubei Gedian Humanwell Pharmaceutical Co., Ltd. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Hubei Gedian Humanwell Pharmaceutical Co., Ltd.?
- FDA issued the letter (MARCS-CMS 725591) on 2026-06-03 and posted it publicly on fda.gov on 2026-06-09.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-06-03 FDA Warning Letter: Hubei Gedian Humanwell Pharmaceutical Co., Ltd. Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-hubei-gedian-humanwell-pharmaceutical-co-ltd-2026-06-03-cgmp
"2026-06-03 FDA Warning Letter: Hubei Gedian Humanwell Pharmaceutical Co., Ltd. Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-hubei-gedian-humanwell-pharmaceutical-co-ltd-2026-06-03-cgmp.
Argus HQ Research. "2026-06-03 FDA Warning Letter: Hubei Gedian Humanwell Pharmaceutical Co., Ltd. Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-hubei-gedian-humanwell-pharmaceutical-co-ltd-2026-06-03-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_hubei_gedian_humanwell_pharmaceutical_co_ltd_2026_06_03_cgmp_2026,
title = {2026-06-03 FDA Warning Letter: Hubei Gedian Humanwell Pharmaceutical Co., Ltd. Cited for CGMP/Active Pharmaceutical Ingredient (API)/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-hubei-gedian-humanwell-pharmaceutical-co-ltd-2026-06-03-cgmp},
note = {Accessed: July 13, 2026}
}